<DOC>
	<DOCNO>NCT00978926</DOCNO>
	<brief_summary>The well-established role vascular endothelial growth factor ( VEGF ) carcinogenesis tumor angiogenesis lead development agent target pathway . Anti-VEGF agent VEGF monoclonal antibody bevacizumab , small molecule VEGF receptor tyrosine kinase inhibitor . Angiogenic factor play key role maintenance lung integrity normal endothelial function . Endothelial dysfunction implicate hypertension , proteinuria retinopathy . One major issue anti-VEGF agent long-term toxicity especially take account lack adequate knowledge area possibility prolong period therapy non-progressing patient . Hypertension proteinuria commonly see patient treat anti-VEGF agent . In addition , investigator also observe relatively high frequency pulmonary air-filled lesion patient malignancy lung treat anti-VEGF agent . Objectives exploratory study 1 ) determine effect anti-vascular endothelial growth factor ( VEGF ) endothelial function 2 ) determine endothelial dysfunction marker early response indicator development hypertension proteinuria 3 ) characterize effect anti-VEGF therapy pulmonary function patient malignancy ( primary secondary ) involve lung patient treat anti-VEGF agent . Pharmacodynamic endpoint assess : blood pressure , brachial artery reactivity , retinal microvessels , microalbuminuria proteinuria , pulmonary function , assess effect anti-VEGF therapy assess brachial artery reactivity , retinal vasculature pulmonary function subset patient receive anti-VEGF therapy . The development marker endothelial dysfunction may result early identification patient non-responders develop toxicity anti-VEGF treatment .</brief_summary>
	<brief_title>A Study Pharmacodynamic Effects Anti-Vascular Endothelial Growth Factor Therapy Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Eligibility Patients receive single agent antiVEGF therapy Signed write informed consent Patients measurable pulmonary malignancy ( primary metastatic ) determine RECIST undergo assessment pulmonary function Patients know allergy intravenous contrast use fluorescein indocyanine green angiography exempt investigation undergo study assessment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Anti-Vascular Endothelial growth factor</keyword>
</DOC>